Chief Scientific Officer · Aclaris Therapeutics, Inc. (ACRS)

Stuart Shanler

A named executive officer of Aclaris Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,808,435

Salary $400,000Stock awards $342,395

FY2017: $534,078

3rd of 3 named executive officers at Aclaris Therapeutics by FY2018 total.

3 named officers on file for Aclaris Therapeutics, FY2018

Stuart Shanler’s pay file — $29

  • 2 fiscal years of pay, line by line
  • ACRS’s disclosed peer group of 43 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aclaris Therapeutics’s whole pay program stands against its peers

  • Aclaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ACRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2019 (DEF 14A).

Free

Get Stuart Shanler’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Stuart Shanler compensation by year

Aclaris Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Aclaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$380,000$400,000
Bonus$0$0
Stock awards$0$342,395
Option awards$0$937,980
Non-equity incentive$142,642$116,400
Pension and deferred compensation$0$0
All other$11,436$11,660
Total$534,078$1,808,435

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aclaris Therapeutics, Inc. DEF 14A filed April 25, 2019, accession 0001558370-19-003262, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aclaris Therapeutics, Inc. filed document, accession 0001558370-19-003262. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2019.

$534K
$1.8M
FY17
FY18
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU15,500$114,545—
RSU2,600$19,214—
RSU1,450$10,716—
Option12,464—$10.66
Option13,459—$28.68
Option31,200—$28.92
Option54,000—$22.09

Per the Outstanding Equity Awards at Fiscal Year-End table in Aclaris Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Aclaris Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Neal WalkerPresident and Chief Executive Officer$4,363,392
David GordonChief Medical Officer$2,116,178
Stuart Shanler · this pageChief Scientific Officer$1,808,435

The full Aclaris Therapeutics compensation record

free company brief

This page is one person within Aclaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Aclaris Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aclaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stuart Shanler's compensation dossier · One-time report. No refunds.